NCT04546126View on ClinicalTrials.gov

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
RadiotracerHypertensionCholesterol
Interventions
DRUG

Dexamethasone (Group 2)

Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.

DRUG

Cosyntropin (Group 3)

Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.

COMBINATION_PRODUCT

PET/CT Scan with FNP-59

FNP-59, a radiotracer, is administered for PET/CT scans.

Trial Locations (2)

48109

RECRUITING

University of Michigan, Ann Arbor

49503

COMPLETED

BAMF Health, Inc., Grand Rapids

All Listed Sponsors
lead

Benjamin Viglianti

OTHER